Sign in
CompletedPhase 2

Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users

Key facts

Who runs it
VA Office of Research and Development
Where
Portland, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 2
People taking part
176 people enrolled
Started
1 May 2019
Ended
15 Oct 2025
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Ibudilast
  • Placebo Oral Tablet
Record updated
2 February 2026

Who can take part

Age
18 years to 55 years
Sex
Women and men
Healthy volunteers
Can take part
Show the full registry criteria (16)Hide the full registry criteria

Who can take part

  • abstinent from all drugs except marijuana and methamphetamine and have a negative urine drug screen on test days
  • Meet diagnosis for recent Methamphetamine-Use Disorder (DSM-V) or does not meet any substance-use disorders

Who cannot take part

  • Any recreational or prescriptive use of psychotropic medications
  • rs6971 genotype that confers low translocator protein (TSPO) binding affinity to prevent unnecessary radiation exposure
  • Participation in any drug study in the last 3 months
  • Clinically significant neurological, endocrine, renal, hepatic, or systemic diseases that would compromise safe participation or confound outcomes
  • Any psychiatric diagnoses or primary psychotic or mood disorders (past depression diagnoses allowed)
  • Any drug use disorder diagnosis besides methamphetamine or tobacco
  • Neurodegenerative diseases that present with neuroinflammation
  • Liver disease requiring medication or medical treatment and/or aspartate or alanine aminotransferase levels greater than 3 times the upper limit
  • Known sensitivity to ibudilast
  • Left handed
  • MRI contraindications
  • Claustrophobia
  • Women who are pregnant or breast-feeding
  • More than 4 weeks abstinent from methamphetamine

Where in United States

  • VA Portland Health Care System, Portland, ORPortland, United States

About the trial

What the trial wants to find out

Addiction to methamphetamine is a serious health problem in the United States. Right now, there are no medications that a doctor can give someone to help them stop using methamphetamine. More research is needed to develop drugs for methamphetamine addiction. Ibudilast (the study drug) is a drug that could help people addicted to methamphetamine.

The 3 groups in the trial

  • PlaceboPlacebo, for comparison

    Placebo Group will be dosed with a placebo oral tablet twice daily for 6 weeks. Participants will have pre/post evaluations for neuroinflammation and associated behaviors

    Treatment: Placebo Oral Tablet

  • IbudilastExisting treatment, for comparison

    Ibudilast Group will be dosed with ibudilast twice daily for 6 weeks. The first 2 weeks will be 20 mg twice daily followed by 4 weeks of 50 mg twice daily. Participants will have pre/post evaluations for neuroinflammation and associated behaviors

  • ControlsNo study treatment, for comparison

    Healthy controls will only undergo baseline evaluations and will not be enrolled in the drug portion of the study.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Brain Function and Connectivity in Methamphetamine Dependence: The Link to Neuroinflammation and the Effects of Ibudilast
Record updated
2 February 2026